Regencell Bioscience Holdings Limited Overview
Regencell Bioscience is a pre-revenue Hong Kong company developing Traditional Chinese Medicine (TCM). It is trying to turn a family-held herbal practice into standardized, registrable liquid formulas for Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD).
Its scientific basis is a formula base and the "Sik-Kee Au TCM Brain Theory®". Both were developed over about 30 years by Sik-Kee Au, the CEO's father, who is the company's contractual research partner. Sik-Kee Au trained as an electrical engineer before becoming a TCM practitioner.
The near-term regulatory goal is proprietary Chinese medicine (pCm) registration in Hong Kong. The company has:
-
no approved products;
-
no granted or pending patents;
-
no distribution capability;
-
about ten employees.
In the market, Regencell is better known as one of 2025's most extreme equity anomalies. The shares rose roughly 48,000–60,000% within weeks, and the company's market value at times exceeded USD 30 billion. A U.S. Department of Justice investigation into trading in the shares followed.
For investors, Regencell is effectively a control-concentrated, very thinly floated option on unproven TCM science.
Company's own description (paraphrased from the FY2026 Form 20-F)
Regencell describes itself as an early-stage TCM bioscience company with a limited operating history. It focuses on researching, developing and commercializing TCM to treat neurocognitive disorders and degenerations, specifically ADHD and ASD.
The company's own disclosures state that:
-
it has no saleable products and has not generated any product revenue;
-
it has not applied for any regulatory approval;
-
it holds no granted or pending patent applications;
-
it has no distribution capabilities or experience.
Operations have been funded mainly by the July 2021 IPO and, from May 2026, by a registered direct offering. The company plans to launch three liquid-based standardized TCM formula candidates, for mild, moderate and severe ADHD/ASD, first in Hong Kong and later in other markets. The FY2025 20-F summary also refers to planned distribution through:
-
clinics;
-
proprietary product registration;
-
TCM wholesalers and retail stores;
-
later expansion to the U.S. and other international markets.
Business model and revenue model
| Dimension | Current state (FY2026) | Intended future state (per filings) |
|---|---|---|
| Revenue mix | 0% product, 0% service, 0% subscription, 0% licensing. No revenue since inception | Product sales of registered pCm liquid formulas. Possibly clinic-based treatment services. Licensing or collaboration revenue is mentioned only as a possibility |
| Value chain position | Upstream research and development (R&D) only. Raw materials are sourced by the TCM Practitioner from Hong Kong vendors | Integrated developer and brand owner. Manufacturing is likely outsourced to GMP-compliant third parties. Distribution through own channels or third parties |
| Customers | — | Pediatric ADHD/ASD patients and their parents and caregivers, TCM clinics, TCM wholesalers and retail stores |
| End-markets | None commercial | Hong Kong TCM market first. The 20-F refers to more than 6,000 TCM stores, wholesalers and other channels in Hong Kong. Later the U.S. and other international markets |
| Manufacturing | None. No contract manufacturer engaged (FY2026 20-F) | Third-party contract manufacturers |
| Sales and marketing | None. The company says it does not currently intend to build a sales force | Third-party commercialization partners, at least initially |
Independent characterization
Regencell is economically a single-asset, founder-controlled research vehicle. Its intellectual property is a family-derived herbal formula set and a trademarked diagnostic theory. Because it holds no patents, protection rests mainly on:
-
trade secrets;
-
trademarks;
-
partnership agreements with the CEO's father.
Its evidence base consists of small, non-blinded, company-run "efficacy trials". These used parent- and caregiver-reported rating scales plus a proprietary 48-item questionnaire (SKATBT-A3) designed by its own R&D team.
Cash operating spend has typically been USD 3–5 million a year. FY2026's reported loss of USD 11.7 million was inflated by legal fees, professional fees and share-based compensation.
The listed equity has been dominated by trading dynamics rather than fundamentals:
-
free float has been roughly 11–12%;
-
short interest has spiked repeatedly;
-
the company says its price swings since 2025 had no link to any change in its financial condition or results.
The company is also a "controlled company" under Nasdaq rules. U.S. holders face a Passive Foreign Investment Company (PFIC) designation for FY2026.
Strategy
Stated strategy (themes paraphrased from filings and releases)
-
Save and improve lives of ADHD/ASD patients. The company aims to become a market leader in ADHD/ASD treatment globally, starting from Hong Kong.
-
Standardize the founder-family formula. It plans to move from personalized prescriptions to three standardized liquid formulas (mild, moderate and severe) suitable for pCm registration.
-
Registration first, then commercialization. The company plans to complete the second efficacy trial, file for pCm registration with Hong Kong regulators, then outsource manufacturing and use third-party channels.
-
Hong Kong first, then international. Later expansion to the U.S. and other markets is planned through Regencell Bioscience North America.
Initiatives announced in the last 24 months (October 2024 – October 2026)
| Date | Initiative | Detail | Status |
|---|---|---|---|
| Jun 2025 | 38-for-1 forward split | Stated aim: improve liquidity and accessibility | Completed |
| Jun 2025 | Board refresh | Margaret Hoor Han Lo appointed independent director | Completed |
| Ongoing (FY2025–FY2026) | Internal control remediation | Hiring and outside U.S. GAAP/SEC experts, oversight of non-recurring transactions, consultant-led control assessment, formal policies | In progress; three material weaknesses remain at FY2026 |
| 30 Mar 2026 | F-3 shelf and USD 500M ATM program | Creates very large potential capacity to issue shares | Shelf effective; ATM unused at 30 Jun 2026 |
| 19–22 May 2026 | USD 20M registered direct offering | Led by a new "fundamental institutional investor" | Closed |
| FY2026 20-F | Possible digital asset treasury policy | Management may consider investing in Bitcoin, Ethereum or crypto exchange-traded products; no purchases made | Under consideration only |
| FY2026 20-F | AI adoption | Company may use AI in operations; risk factor added | Exploratory |
| Ongoing | Second efficacy trial in Hong Kong | Standardized formulas; company says it is unsure whether a redesign will be needed | Ongoing; no completion date disclosed |
Sustainability and ESG commitments: none disclosed beyond a generic risk factor.
Cost programs with targets: none disclosed.
Medium-term financial targets and guidance: none. The company gives no revenue, profitability or registration timeline. A 2022 sponsored research note referred to a four-year timeframe to commercialize and obtain pCm registration; that timeframe has passed without a filing.
Products & Services
None of the items below is approved or commercially available. All are development candidates or brand assets.
Trial endpoints used in the efficacy trials (FY2026 20-F):
-
SKATBT-A3 (proprietary);
-
Autism Treatment Evaluation Checklist (ATEC);
-
Gilliam Autism Rating Scale (GARS);
-
Vanderbilt ADHD Diagnostic Parent Rating Scale (VADRS);
-
SNAP-IV 26-item Parent Rating Scale.
The company acknowledges these depend on data reported by parents and caregivers, which may be biased.
Product Portfolio
| # | Product / asset | Segment | Description | Development status | Target customer | Year | Pricing |
|---|---|---|---|---|---|---|---|
| 1 | Standardized liquid TCM formula: Mild ADHD/ASD | TCM R&D | Orally administered liquid herbal formula derived from the TCM Practitioner's base formula plus a standardized adjustable component. Dosed twice daily for a 3-month course in trials | In the second efficacy trial (non-blinded); trial still ongoing per FY2026 20-F; no regulatory filing | Children and patients with mild ADHD/ASD; parents and caregivers | Candidates defined before the 2021 IPO | — |
| 2 | Standardized liquid TCM formula: Moderate ADHD/ASD | TCM R&D | Same platform, calibrated for moderate severity | Same as above | Moderate ADHD/ASD | Before IPO | — |
| 3 | Standardized liquid TCM formula: Severe ADHD/ASD | TCM R&D | Same platform, calibrated for severe severity | Same as above | Severe ADHD/ASD | Before IPO | — |
| 4 | Personalized TCM formula | TCM R&D | Practitioner-adjusted individual prescriptions; the basis of the first study (2019) and first efficacy trial | Completed; company states its results may not predict outcomes for the standardized formulas | Individual patients | 2019 | — |
| 5 | RGC-COV19™ (internal JV code RGCA-CV01) | Infectious disease (historical) | Liquid TCM formula targeting mild-to-moderate COVID-19 symptoms over a 6-day course | EARTH-A (37 patients) and EARTH-B (51 patients) company-run trials in 2021–2022, not peer reviewed. No current development disclosed in the FY2026 20-F, which focuses solely on ADHD/ASD | COVID-19 patients in ASEAN countries, India, Japan, Australia and New Zealand (via the JV) | 2020–2022 | — |
| 6 | SKATBT-A3 (Sik-Kee Au TCM Brain Theory® for ADHD/ASD Assessment) | Assessment tool | 48-item questionnaire built by the company's R&D team to capture conditions the Practitioner observes under his brain theory | Used as a trial endpoint | Internal research use | 2021–2022 | Not applicable |
| 7 | Trademark: 腦還原® ("brain restoration") | Brand | Registered with the Hong Kong Registrar of Trade Marks | Registered | Consumer brand | — | Not applicable |
| 8 | Trademarks: RGC Regencell® and RGC® | Brand | Corporate and product marks, Hong Kong | Registered | Not applicable | — | Not applicable |
| 9 | Trademark: Sik-Kee Au TCM Brain Theory® | Brand / IP | Theory underpinning the formulas (shown with ™ before IPO, ® by 2026) | Registered | Not applicable | — | Not applicable |
“—” = not publicly disclosed.
| Study | Design | Key reported outcome | Source |
|---|---|---|---|
First research study (2019) | Personalized formula, 7 pediatric patients, Hong Kong | Assessment scores fell; no controlled data | Renaissance Capital; CEO letter Aug 2021 |
First efficacy trial | Personalized formula, 3 months | Mean improvement of 30% in ADHD symptoms (VADRS) and 37% in ASD symptoms (ATEC) | Company release via QuantisNow |
Second efficacy trial (interim, Sep 2022) | Standardized formulas, non-blinded, 3 months, twice daily | Mean improvement of 37% on SKATBT-A3 | Business Wire, 12 Sep 2022 |
EARTH-A | RGC-COV19™, 1 Oct 2021 – 31 Jan 2022, 37 patients | 97.3% complete symptom elimination within 6 days | Company release |
EARTH-B | RGC-COV19™, 30 Jan – 31 Mar 2022, 51 patients | 94.1% complete symptom elimination within 6 days | Company release |
EARTH-A and EARTH-B combined | 88 patients | 95.5% complete symptom elimination within 6 days; 29.7% tested negative within 6 days | Company release |
Financial Detail
Group Entities
| Entity | Jurisdiction | Ownership | Function |
|---|---|---|---|
Regencell Bioscience Holdings Limited | Cayman Islands | Listed parent | Holding company; Nasdaq issuer |
Regencell Bioscience Limited | Hong Kong | 100% | Main operating subsidiary: R&D, efficacy trials, partnership with the TCM Practitioner |
Regencell Limited | Hong Kong | 100% | Hong Kong subsidiary (function not separately described in sources reviewed) |
Regencell Bioscience North America Limited | British Virgin Islands | 100% | Vehicle for intended North American expansion |
Regencell (BVI) Limited | British Virgin Islands | Owned by the CEO (not a subsidiary) | CEO's holding vehicle for his controlling stake |
Former COVID-19 JV with Honor Epic Enterprises (company releases referred to a "Regencell Asia" entity) | Not specified | Formerly 60% | Not named among the subsidiaries in the FY2026 20-F definitions. Current status (dissolved, disposed or dormant) is not publicly disclosed in the sources reviewed |
Segment Revenue
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
TCM R&D segment revenue (USD Mn) | 0 | 0 | 0 |
Total revenue (USD Mn) | 0 | 0 | 0 |
Results by Segment
| Segment metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment pre-tax loss (USD Mn) | -4.36 | -3.58 | -11.70 |
Share of total revenue (%) | 0 | 0 | 0 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Gross profit (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Research and development (USD Mn) | 2.51 | 1.58 | 1.07 | 0.95 | 1.30 |
General and administrative (USD Mn) | 5.08 | 4.43 | 3.55 | 2.81 | 10.42 |
Selling and marketing (USD Mn) | 0.03 | 0.26 | 0.13 | 0.01 | 0.01 |
Total operating expenses (USD Mn) | 7.62 | 6.27 | 4.74 | 3.77 | 11.72 |
Operating income (USD Mn) | -7.62 | -6.27 | -4.74 | -3.77 | -11.72 |
Interest and other income (USD Mn) | 0.02 | 0.09 | 0.37 | 0.19 | 0.02 |
Pre-tax income (USD Mn) | -7.59 | -6.06 | -4.36 | -3.58 | -11.70 |
Net income (USD Mn) | -7.59 | -6.06 | -4.36 | -3.58 | -11.70 |
Net income attributable to Regencell (USD Mn) | -7.42 | -5.87 | -4.30 | -3.58 | -11.70 |
Comprehensive loss (USD Mn) | — | — | — | -3.60 | -11.68 |
Share-based compensation (USD Mn) | — | 0.92 | 0.45 | 0.24 | 3.20 |
Depreciation (USD Mn) | — | 0.29 | 0.31 | 0.08 | — |
ROU asset amortization (USD Mn) | — | 0.48 | 0.44 | 0.32 | — |
EBITDA, derived (USD Mn) | -7.02 | -5.50 | -3.99 | -3.38 | — |
EPS basic, split-adjusted (USD) | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 |
EPS diluted, split-adjusted (USD) | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 |
Dividends per share (USD) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Net loss growth YoY (%) | 462 | -20 | -28 | -18 | 227 |
Operating expense growth YoY (%) | 452 | -18 | -24 | -20 | 211 |
Balance Sheet and Share Count (M)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (USD Mn) | — | — | — | 5.76 | — |
Cash and equivalents (USD Mn) | — | — | — | — | 14.19 |
Total liabilities (USD Mn) | — | — | — | 0.90 | — |
Shareholders' equity (USD Mn) | — | — | — | 4.86 | — |
Goodwill and intangibles (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Shares outstanding (M) | 494.49 | 494.49 | 494.49 | 494.49 | 495.88 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (USD Mn) | — | — | -4.00 | -3.11 | — |
Equity raised, net (USD Mn) | 0 | 0 | 0 | 0 | 18.62 |
Dividends paid (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%)
| Ratio | FY2025 | Basis |
|---|---|---|
ROE (%) | -74 | Net loss / ending equity (USD 3.58M / USD 4.86M) |
ROA (%) | -62 | Net loss / ending total assets (USD 3.58M / USD 5.76M) |
Debt / equity | Approx. 0 (excluding leases) | No borrowings identified |
Asset turnover | 0 | No revenue |
Geographic Revenue
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Hong Kong revenue (USD Mn) | 0 | 0 | 0 |
North America revenue (USD Mn) | 0 | 0 | 0 |
Rest of world revenue (USD Mn) | 0 | 0 | 0 |
Total revenue (USD Mn) | 0 | 0 | 0 |
Share Price
| Metric | Oct2021 | Oct2022 | Oct2023 | Oct2024 | Oct2025 | Jul2026 |
|---|---|---|---|---|---|---|
Share price, split-adjusted (USD) | 0.35 | 0.72 | 0.42 | 0.17 | 16.65 | 5.98 |
Share Price (Mar2025–Mar2026)
| Metric | Mar2025 | Apr2025 | May2025 | Jun2025 | Dec2025 | Mar2026 |
|---|---|---|---|---|---|---|
Month-end price, split-adjusted (USD) | 0.84 | 1.58 | 23.08 | 17.04 | 21.00 | 25.43 |
Share Price & Returns
| Horizon | Approx. return | Basis |
|---|---|---|
1 year | About -60% to -65% | Oct 2025 (16.65) to Sep 2026 (about 5.8). iocharts shows a 12-month CAGR of -57.3% |
3 years | About +1,300% | Oct 2023 (0.42) to about 5.8. iocharts shows a 3-year CAGR of 136% |
5 years | About +1,550% | Oct 2021 (0.35) to about 5.8. iocharts shows a 5-year CAGR of 36%, which conflicts with this calculation (possibly a different base); discrepancy noted |
Since IPO | About +2,200% | IPO at USD 9.50 pre-split (USD 0.25 adjusted) |
From all-time high | About -92.6% | Closing high USD 78.00 (17 Jun 2025) |
Valuation Multiples
| Multiple | Regencell |
|---|---|
P/E | Not meaningful (loss) |
EV/EBITDA | Not meaningful (negative EBITDA) |
EV/Sales | Not meaningful (zero sales) |
P/B | Several hundred to about 2,300 times (MarketBeat about 684x; iocharts about 2,328x; varies with the equity base and date) |
Market cap / cumulative 5-year R&D | About 385 times (USD 2.85B / USD 7.4M) |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | No sell-side coverage (Simply Wall St: 0 analysts). Algorithmic "targets" on aggregator sites are not analyst consensus |
Dividend history and policy | No dividends ever paid; none expected for the foreseeable future (20-F) |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Short interest | Peaked at about 2.26M shares (Aug 2025); 606,522 shares (13 Mar 2026); about 4% of float (MarketBeat) |
Trading halts | Multiple volatility trading pauses in 2025–2026 |
Equity issuance capacity | USD 500M ATM (unused at 30 Jun 2026); remaining F-3 shelf capacity |
Analyst Conclusions
Management guidance and consensus
Management guidance: none. The company says it expects operating losses to increase for the foreseeable future as research continues and if commercialization begins.
Consensus: no analyst coverage, so no consensus growth expectations exist.
Bull case
-
Funded and debt-free for the first time since the IPO. About USD 14.2M of unused proceeds compares with a core cash burn of roughly USD 3–5M a year, excluding legal costs. The USD 500M ATM could fund a properly designed, controlled trial program far beyond anything attempted to date.
-
Legal overhang easing. The securities class action was voluntarily dismissed on 14 September 2026. If the DOJ investigation ends without charges against the company, governance-driven costs (USD 3.13M of extra professional fees in FY2026) should fall away.
-
Real unmet need and a culturally receptive home market. There is no approved therapy for core ASD symptoms. Parents in Hong Kong and Asia widely accept TCM. A first registered pediatric ADHD/ASD pCm in Hong Kong would be a differentiated asset, and trademarks such as 腦還原® are already registered.
Bear case
-
The valuation is unconnected to the asset. About USD 2.85B of market value rests on zero revenue, no patents and cumulative five-year R&D of about USD 7.4M. The company itself says its price moves are unrelated to its fundamentals. The thin float (about 11%) and repeated squeezes make price discovery unreliable.
-
Science and governance credibility deficits. The trials are non-blinded and rely on parent-reported, partly proprietary endpoints. The IP comes from the CEO's father. Three material weaknesses persist. The auditor changed in FY2026. A DOJ trading investigation remains open as far as public disclosure shows.
-
Dilution and tax overhang. The May 2026 placement was priced at a 27% discount, and the shares fell about 75% within weeks. The USD 500M ATM is large relative to the float. PFIC status for FY2026 and the 88.3% controlling stake limit the institutional buyer base.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| Second efficacy trial completion or redesign | First standardized-formula evidence since the September 2022 interim readout |
| Any pCm registration filing with Hong Kong regulators | Would be the first regulatory step ever taken |
| DOJ investigation developments | Possible fines or penalties; management distraction |
| ATM usage disclosed in 6-K and 20-F filings | Pace of dilution |
| Digital asset treasury decision | Could change the risk profile and PFIC analysis |
| Material weakness remediation | Audit quality and listing risk |
| First-half FY2027 results (expected around May–June 2027) | Burn rate after the legal costs |
| Changes in insider or free-float structure | Liquidity and susceptibility to squeezes |
| Nasdaq or SEC actions on trading anomalies | Listing risk |
Analyst verdict
Regencell Bioscience is best analysed as two separate objects that happen to share a ticker.
The first is an operating company. It is a roughly ten-person Hong Kong research outfit trying to standardize and register a family-derived herbal formula for ADHD and autism. Over five years it has spent about USD 7.4 million on R&D and holds no patents. Its evidence is non-blinded and largely reported by parents. It has never applied for regulatory approval or generated a dollar of revenue.
Its economics have been frugal, with operating expenses of USD 3–5 million a year before FY2026. Its balance sheet is now clean and modestly funded after the May 2026 placement. The scientific premise is unproven rather than disproven. A credible path to value would require a properly controlled trial, a pCm filing and a commercialization partner. None of these is yet in view, and the second efficacy trial has run since at least 2022 without a final readout.
The second object is the listed equity. It is an 88%-insider-owned, about 11%-float instrument that has moved from USD 0.09 to USD 78 and back to about USD 6 in eighteen months. These swings are what the company itself calls unrelated to its operations, and they have drawn a DOJ investigation.
Even after a 92% fall from its peak, the market capitalization of about USD 2.85 billion still implies a value several hundred times book. The company can also issue up to USD 500 million of stock through its at-the-market program.
On the evidence in the filings, the equity offers no fundamental margin of safety. It carries asymmetric downside from three sources: dilution, regulatory or legal developments, and a normalization of float dynamics. Upside depends on controlled clinical validation that the company has not yet attempted.
Verdict: a speculative, governance-impaired, pre-clinical-equivalent TCM developer whose equity is not underwritable on fundamentals. For institutional purposes it should be monitored only for:
-
a controlled trial readout;
-
a regulatory filing;
-
resolution of the DOJ matter.
All figures are in USD with a fiscal year ending 30 June unless stated otherwise. Third-party market data (prices, market capitalization, ownership aggregates) is approximate and dated as noted.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Age |
|---|---|---|---|---|
Yat-Gai Au | Founder, Chairman of the Board and CEO | Since 2014 | Studied at UC Berkeley's Haas School of Business; worked at Deutsche Bank in the 1990s; has spoken publicly about having ADHD and dyslexia (Bloomberg via WION) | 54 (MarketScreener) |
James Wai Hong Chung | Chief Operating Officer and executive director; also styled Chief Scientific Officer in 2021 releases | COO since 1 Aug 2021; director since 28 Dec 2023 | Corporate IR contact on 2021 releases | 49 (MarketScreener) |
Yat-Pui Au | Chief Business Officer | CBO since 1 Feb 2023 (previously senior vice president) | More than 24 years in strategic management and business operations, including physical security and property management; began as a consultant analyst at Computer Sciences Corporation; BA in Legal Studies, UC Berkeley; brother of the CEO | — |
Chief Financial Officer | — | — | The CFO's identity was not confirmed in the sources reviewed. The FY2026 20-F reports material weaknesses, including a shortage of staff with U.S. GAAP and SEC reporting expertise | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Since | Independence | Notes |
|---|---|---|---|---|
Yat-Gai Au | Chairman and CEO | 2014 | Not independent; controlling shareholder | Chair and CEO roles combined |
James Wai Hong Chung | Executive director (COO) | 28 Dec 2023 | Not independent | Replaced Dr. Yi-Chung Chao; director fee HK$84,000 a year in cash |
Dr. William Wing-Yan Lo, JP | Independent non-executive director | 13 Dec 2021 | Independent | Age 65 (MarketScreener) |
Margaret Hoor Han Lo | Independent non-executive director | 30 Jun 2025 | Independent | Replaced Mr. Niewiadomski, who resigned for personal reasons |
Directors' Remuneration
| Item | Detail | Source |
|---|---|---|
Aggregate executive and director pay, FY2026 | Not publicly disclosed in the sources reviewed. Foreign private issuers disclose aggregate figures in Item 6 of the 20-F; no proxy statement (DEF 14A) is filed | — |
Share-based compensation, FY2026 | About USD 3.2M (G&A share-based compensation up USD 3.02M year on year) | FY2026 20-F; Panabee |
First-half FY2026 share-based compensation (G&A) | USD 1.63M, against 0.22M in the first half of FY2025 | First-half FY2026 release |
Director fee: James Chung | HK$84,000 a year | 6-K, Jan 2024 |
Bonuses | FY2026 R&D payroll up about USD 0.42M and G&A payroll up USD 1.47M, attributed to bonuses and annual salary adjustments | FY2026 20-F |
Major Shareholders
| Holder | Stake | Source / date |
|---|---|---|
Yat-Gai Au (via Regencell (BVI) Limited and spouse) | 88.3% | FY2026 20-F |
Insiders (aggregate, as reported by MarketBeat) | 2.00% | MarketBeat. Conflicts with the 20-F; MarketBeat appears to exclude the BVI holding |
Free float | About 11.2% | MarketScreener |
Institutions (aggregate) | About 0.13% | MarketBeat |
Named 13F holders (small) | Vident Advisory LLC: 29,934 shares. Bank of America Corp: 17,172 shares. Seven Fleet Capital Management: new stake of about USD 92k (Q4 2025). Greenfield Savings Bank | MarketBeat 13F digest, 2026 |
New institutional investor (May 2026 registered direct offering) | About 936,000 shares (USD 19M / USD 20.30); investor not named | 6-K, 19 May 2026 |
Univest Securities (May 2026 registered direct offering) | About 49,000 shares (USD 1M) | 424B5 |
Samuel Chen (early Zoom investor) | Described as a major backer in 2022; current stake not disclosed | Zacks SCR, 2022 |
Competitive Landscape
Key Competitors
| # | Competitor | Segment overlap | Key products / position | Revenue (latest FY, approx.) |
|---|---|---|---|---|
| 1 | Takeda Pharmaceutical | ADHD stimulants | Vyvanse/Elvanse (lisdexamfetamine), Mydayis; global ADHD leader (Vyvanse now generic in the U.S.) | — |
| 2 | Johnson & Johnson | ADHD stimulants | Concerta (methylphenidate extended release) | — |
| 3 | Novartis | ADHD stimulants | Ritalin, Focalin (methylphenidate franchise) | — |
| 4 | Supernus Pharmaceuticals | ADHD non-stimulant | Qelbree (viloxazine) | — |
| 5 | Cingulate Inc. | ADHD (development) | CTx-1301 (dexmethylphenidate) | Pre-revenue |
| 6 | Axsome Therapeutics | ADHD (development) | Solriamfetol in ADHD trials | — |
| 7 | Beijing Tong Ren Tang group (incl. Tong Ren Tang Chinese Medicine, HKEX: 3613) | TCM manufacturing and retail, Hong Kong and China | Heritage TCM brand with Hong Kong retail network | — |
| 8 | China Traditional Chinese Medicine Holdings (HKEX: 0570) | TCM granules and pCm | Concentrated TCM granules | — |
| 9 | PuraPharm (HKEX: 1498) | Hong Kong TCM granules | Nong's® concentrated Chinese medicine granules | — |
| 10 | Eu Yan Sang (private) | TCM retail, Asia | TCM retail chain | — |
| 11 | Behavioral and educational therapy providers | ASD (no approved drug treats core ASD symptoms) | Applied behavior analysis (ABA), speech and occupational therapy | Fragmented |
“—” = not publicly disclosed.
Peer Comparison FY2026
| Metric | Regencell (FY2026) | Supernus (2024) | Takeda (FY2024) | Novartis (2024) |
|---|---|---|---|---|
Revenue | USD 0 | About USD 0.66B | About JPY 4.58T | About USD 50.3B |
Operating margin | Not meaningful (operating loss USD 11.72M) | — | — | — |
R&D intensity | Not meaningful (R&D USD 1.30M) | — | — | — |
Approved products | 0 | Multiple CNS drugs | Large portfolio | Large portfolio |



